Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
46.35 EUR | 0.00% | +0.32% | -17.82% |
Mar. 18 | Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar | MT |
Mar. 18 | Fresenius Settles With Johnson & Johnson to Market Stelara Alternative | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-17.82% | 803M | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-5.11% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
-8.77% | 11.06B |
- Stock
- Equities
- Stock Formycon AG - Xetra
- News Formycon AG
- Formycon's Eye Diseases Treatment Receives UK Marketing Authorization